

Multiple System Atrophy: cognitive impairment and comparison to Parkinson's Disease




Pane C¹, Costabile T¹, Lieto M¹, Reia A¹, De Michele G¹, Filla A¹, Saccà F¹.

¹Department of Neurosciences, Odontostomatological and Reproductive Sciences, University Federico II, Naples, Italy

Multiple System Atrophy

- neurodegenerative disorder
- parkinsonism
- cerebellar impairment
- autonomic dysfunction



COGNITIVE IMPAIRMENT (CI) COULD BE A CONSISTENT MSA FEATURE?

MSA AND PD PATIENTS HAVE DIFFERENT COGNITIVE ABILITIES?

10 Multiple System Atrophy (MSA) patient

10 Parkinson disease (PD) patients

10 healthy controls (HC)

➤ Pata Rate

➤ 9 Hole Pegboard Test

Neuropsychological battery

Global Evaluation: Montreal Cognitive Assessment
Language: Naming nouns and Pointing
Intelligence: Raven's Colored Progressive Matrices
Executive Function: Symbol Digit Modalities Test, Trail Making Test, Phonemic and Semantic fluencies, Attentional Matrices
Memory: Digit span, Modified 10/36 spatial recall test, Rey's auditory verbal learning test
Visuospatial Function: Segment length discrimination, Mental rotation

MSA, PD and HC were comparable for age, sex distribution, and education

MSA
 MoCA (p=0.002),
 Ray's short term memory (p=0.004)
 Semantic fluencies (p=0.014)
 Attentional Matrices (p=0.01)
 Trail Making Test B (p=0.030)
 Symbol Digit Test (p=0.006)



HC

MSA PATIENTS SHOWED A RELEVANT CI CONCERNING EXECUTIVE FUNCTIONS, SHORT-TERM MEMORY, AND GLOBAL FUNCTIONING

MSA
 MoCA (p=0.046)



PD

AT GLOBAL ASSESSMENT MSA SHOWED GRATER CI THAN PD.

PD
 Symbol Digit Test (p=0.008)



HC

PD PATIENTS, DESPITE A LONG PERIOD OF ILLNESS, HAVE LIMITED CI IMPAIRMENT, WITH EXCLUSIVE ALTERATION OF THE SYMBOL DIGIT MODALITIES TEST

Bibliography

- Siri C, Duerr S, Canesi M, et al. A cross-sectional multicenter study of cognitive and behavioural features in multiple system atrophy patients of the parkinsonian and cerebellar type. J Neural Transm 2013; 120: 613–618
- Dujardin K, Defebvre L, Krystkowiak P, Degreef JF, Destee A. Executive function differences in multiple system atrophy and Parkinson's disease. Parkinsonism Relat Disord 2003; 9: 205–211

Test	K-W (p)	HC	MSA	CNTRL vs MSA (p)	PD	CNTRL vs PD (p)	MSA vs PD (p)
Moca	0.002	24.9±2.8	19.1±3.2	0.004	22.3±2.5	0.144	0.044
Raven	0.148	29.9±3.2	24.6±9.9	NP	24.1±6.6	NP	NP
Naming	0.737	14.3±0.8	14±1.5	NP	13.5±1.7	NP	NP
Pointing	0.317	23.9±0.3	23.6±0.8	NP	24±0	NP	NP
DigitSpan	0.807	5.2±0.8	5.3±0.8	NP	5.1±0.7	NP	NP
Reylmm	0.011	39.7±6.4	28.9±5.5	0.006	34.8±9	0.258	0.240
ReyDiff	0.594	8.3±3.2	6.6±2.4	NP	7.9±2.9	NP	NP
1036lmm	0.209	20.7±5.1	16.7±5.9	NP	18.7±4.8	NP	NP
1036Diff	0.131	7.4±2.4	5.4±2.6	NP	6.5±1.6	NP	NP
Fonemic Fluency	0.061	38.2±14.9	22.5±12.8	NP	29.2±9.8	NP	NP
Fonemic Fluency Corrected	0.075	38.2±14.9	23.2±13.3	NP	29.2±9.8	NP	NP
Semantic Fluency Raw	0.021	21.725±4.9	14.275±4.3	0.008	18.4±6.4	0.380	0.302
Semantic Fluency Corrected	0.039	21.7±4.9	14.4±4.8	0.018	18.4±6.4	0.380	0.398
Attentional Matrices Raw	0.001	55.5±3.9	34.8±16.5	0.002	52.6±5.2	0.186	0.014
Attentional Matrices Corrected	0.016	55.5±3.9	44.7±14.1	0.012	52.6±5.2	0.186	0.320
TMT-A	0.004	41.5±17.9	108±67	0.004	47.5±26	1.000	0.014
TMT-A corretta	0.115	56.4±25.2	79.9±35.5	NP	55.0±24.2	NP	NP
TMT-B	0.001	104.6±36.2	315.4±134.3	0.002	164.4±112.3	0.346	0.038
TMT-B corretta	0.500	104.6±36.3	253.1±107.2	NP	164.4±112.4	NP	NP
SDMT	0.002	40.5±8.2	24.3±8.7	0.006	28.2±8.3	0.012	0.424
SDMT corretta	0.004	40.5±8.3	25.0±8.9	0.010	28.2±8.4	0.012	0.614

Comparison between the groups of patients analyzed with the Kruskal-Wallis Test and post-hoc analysis with the mann-Whitney

SD = standard deviation, Moca = Montreal Cognitive Assessment, FF = Fonemic Fluency, FS = Semantic Fluency, MA = Attentional matrix, TMT = Trail Making Test, SDMT = Symbol Digit Modalities Test

Test	Group (n,%)		
	MSA	PD	Control
Immediate Recall	6 (60%)	4 (40%)	1 (10%)
Semantic Fluency Raw	5 (50%)	2 (20%)	0%
Semantic Fluency Corrected	4 (40%)	2 (20%)	0%
Attentional Matrices Raw	5 (50%)	0%	0%
Attentional Matrices Corrected	2 (20%)	0%	0%
Trail Making Test A	6 (60%)	1 (10%)	1 (10%)
Trail Making Test B	7 (70%)	2 (20%)	1 (10%)
Symbol Digit Modalities Test Raw	10 (100%)	7 (70%)	3 (30%)
Symbol Digit Modalities Test Corrected	10 (100%)	7 (70%)	3 (30%)

Number of patients and controls with impaired test results

THESE EVIDENCES RAISE THE POSSIBILITY THAT CI MAY CONTRIBUTE TO THE CLINICAL SPECTRUM OF MSA TO A GREATER EXTENT THAN IT IS CURRENTLY THOUGHT.